EAGER: Engineering Optical Nanobiosensors for Detection of Coronavirus Proteases

EAGER：工程光学纳米生物传感器用于检测冠状病毒蛋白酶

• 批准号: 2125030
• 负责人: Stefan Bossmann
• 金额: $ 30万
• 依托单位: University of Kansas Medical Center Research Institute Inc
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-03-15 至 2022-10-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2125030&HistoricalAwards=false
• 关键词: EAGER; Engineering; Optical; Nanobiosensors; Detection

Coronaviruses have emerged as major pathogens of respiratory disease outbreaks, including most recently COVID-19 disease. Current assays for detection of the SARS-CoV-2 coronavirus, the causative agent of COVID-19 disease, are based on reverse transcriptase-coupled polymerase chain reaction (RT-PCR) or immunoassays which use antibodies to detect viral antigens. However, these assays have limited capacity to discriminate between active and past infections. The goal of this project is to design and validate nanobiosensors capable of reporting active coronavirus infections. Optical nanobiosensors will be developed that detect two signature proteases of SARS-CoV-2. These optical nanobiosensors are anticipated to provide quantitative assessment of active viral load, such that disease trajectories can be measured.PCR-based and immunological methods are limited in their ability to distinguish between patients with active coronavirus infection and patients that have survived the disease. Moreover, immunoassays are hampered by the incomplete specificity of currently available antibodies. A critical need exists for a technology that is capable of detecting the activity of a coronavirus in a "liquid biopsy" such as plasma, serum, sputum or exhaled breath condensate. The hypothesis of this research is that proteolytic activities of SARS-CoV-2 signature proteases PLpro and 3CLpro will provide a real-time, quantitative marker of active viral infection. Optical nanobiosensors specific for these proteases will be developed and validated, leveraging the optical properties of magnetic Fe/Fe3O4 core/shell nanoparticles linked to fluorophores and FRET-quenchers. Subsequent in vitro validation will utilize biosamples from infected cell cultures and pre-clinical models. This research builds on prior work by the Kansas State University team who developed patented bionanosensor technology for the ultra-sensitive detection of proteases and post-translational modifications, which has demonstrated capacity to detect proteases (e.g., arginase) in the sub-femtomolar range.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

冠状病毒已成为呼吸道疾病爆发的主要病原体，包括最近的COVID-19疾病。目前用于检测SARS-CoV-2冠状病毒（COVID-19疾病的病原体）的检测方法是基于逆转录酶偶联聚合酶链反应（RT-PCR）或使用抗体检测病毒抗原的免疫测定法。然而，这些检测方法区分活动性感染和既往感染的能力有限。该项目的目标是设计和验证能够报告活动性冠状病毒感染的纳米生物传感器。光学纳米生物传感器将被开发出来，用于检测SARS-CoV-2的两种标志性蛋白酶。这些光学纳米生物传感器有望提供活性病毒载量的定量评估，从而可以测量疾病轨迹。基于PCR和免疫学的方法在区分患有活性冠状病毒感染的患者和已经存活的患者的能力方面受到限制。此外，免疫测定受到目前可用抗体的不完全特异性的阻碍。迫切需要一种能够检测诸如血浆、血清、痰或呼出气冷凝物的“液体活检”中的冠状病毒的活性的技术。本研究假设SARS-CoV-2特征蛋白酶PLpro和3CLpro的蛋白水解活性将提供活性病毒感染的实时定量标记。将开发和验证这些蛋白酶的光学纳米生物传感器，利用磁性Fe/Fe 3 O 4核/壳纳米颗粒与荧光团和FRET猝灭剂的光学特性。随后的体外验证将使用来自感染细胞培养物和临床前模型的生物样本。这项研究建立在堪萨斯州立大学团队先前的工作基础上，该团队开发了用于蛋白酶和翻译后修饰的超灵敏检测的生物纳米传感器专利技术，该技术已证明有能力检测蛋白酶（例如，该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。

项目成果

Optical biosensing of markers of mucosal inflammation.

• DOI: 10.1016/j.nano.2021.102476
• 发表时间: 2022-03
• 期刊: NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
• 影响因子: 5.4
• 作者: Covarrubias-Zambrano, Obdulia;Motamedi, Massoud;Ameredes, Bill T.;Tian, Bing;Calhoun, William J.;Zhao, Yingxin;Brasier, Allan R.;Kalubowilage, Madumali;Malalasekera, Aruni P.;Yapa, Asanka S.;Wang, Hongwang;Culbertson, Christopher T.;Troyer, Deryl L.;Bossmann, Stefan H.
• 通讯作者: Bossmann, Stefan H.

Detection of early-stage lung cancer with an in vitro panel of activity-based biosensors to measure inflammatory protease enzymes.

使用一组基于活性的生物传感器来测量炎症蛋白酶来检测早期肺癌。

• DOI: 10.1200/jco.2022.40.16_suppl.e20551
• 发表时间: 2022
• 期刊: Journal of Clinical Oncology
• 影响因子: 45.3
• 作者: Dempsey, Paul W.;Aparicio, Cristina-Mihaela Sandu;Hantula, Spencer;Covarrubias, Jose;Varghese, Sunita;Neri, Raul;Ehsan, Sumia;Covarrubias-Zambrano, Obdulia;Bossmann, Stefan H.
• 通讯作者: Bossmann, Stefan H.